FY2024 Earnings Estimate for TSE:FRX Issued By HC Wainwright

Fennec Pharmaceuticals Inc. (TSE:FRX) – Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Fennec Pharmaceuticals in a report released on Tuesday, December 17th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the year, down from their prior forecast of $0.11. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.01 EPS and FY2025 earnings at ($0.55) EPS.

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 1.3 %

Shares of FRX stock opened at C$8.57 on Thursday. The company has a 50-day moving average of C$7.12 and a two-hundred day moving average of C$7.69. The firm has a market cap of C$234.48 million, a PE ratio of 85.70 and a beta of 0.25. Fennec Pharmaceuticals has a 1-year low of C$5.65 and a 1-year high of C$15.43. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.

Insider Transactions at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of C$3.43 per share, with a total value of C$54,248.88. Company insiders own 16.20% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.